KR900004339A - 의약제 - Google Patents

의약제 Download PDF

Info

Publication number
KR900004339A
KR900004339A KR1019890012465A KR890012465A KR900004339A KR 900004339 A KR900004339 A KR 900004339A KR 1019890012465 A KR1019890012465 A KR 1019890012465A KR 890012465 A KR890012465 A KR 890012465A KR 900004339 A KR900004339 A KR 900004339A
Authority
KR
South Korea
Prior art keywords
compound
group
alkyl
therapeutic agent
hydrogen atom
Prior art date
Application number
KR1019890012465A
Other languages
English (en)
Inventor
해롤드 코터스 아이언
윌리엄 옥스포드 알렉젠더
챨스 노스 피터
브라이언 타이어즈 마이클
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR900004339A publication Critical patent/KR900004339A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

의약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 약물 또는 남용물 탐닉으로 인한 금단 증후군을 완화하거나 약물 또는 남용물 의존성을 억제하는데 있어서, 치료하고, 또한(또는) 유효 성분으로서 하기 일반식(Ⅰ)의 화합물 또는 생리학상 허용되는 이들의 염 또는 용매화합물로 되는 치료제.
    상기 식에서, Im 은 다음의 구조식을 갖는 이미다졸릴기를 나타내고,
    R1은 수소 원자이거나, 또는 C1-6알킬, C3-6알케닐, C3-10알키닐, C3-7시클로알킬, C3-7시클로알킬 C1-4알킬, 페닐, 페닐 C1-3알킬, 페닐메톡시메틸, 페녹시에틸 페녹시베틸, -CO2R5-COR5-CONR5R6또는 SO2R5(여기에서, R5및 R6는 서로 동일하거나 또는 상이한 것으로서, 이들 각각은 수소 원자, C1-6알킬 또는 C3-7시클로알킬기이거나, 또는 페닐 또는 페닐 C1-4알틸기로서, 여기에서 페닐기는 1개 이상의 C1-4알킬, C1-4알콕시 또는 히드록시기 또는 할로겐 원자에 의해 임의적으로 치환될 수 있되, 단 R1이 -CO2R5또는 -SO2R5기를 나타내는 경우에는 R5가 수소 원자일 수 없음)중에서 선택되는 기이고, R2, R3및 R4로 나타낸 기중 1개는 수소 원자이거나 또는 C1-6알킬, C3-7시클로알킬, C3-6알케닐, 페닐 또는 페닐 C1-3알킬기며, 나머지 2개의 기는 서로 동일하거나 또는 상이한 것으로서, 수소 원자 또는 C1-6알킬기를 나타내고, n은 2 또는 3을 나타낸다.
  2. 제1항에 있어서, 일반식(Ⅰ)의 화합물중 R1은 수소 원자이거나, 또는 C1-4알킬, C3-4알케닐, C3-4알키닐, C5-6시클로알킬, C5-6시클로알킬메틸, 페닐 C1-2알킬, 페닐메톡시메틸, N,N-디C1-4알킬카르복스아미드 또는 C1-3알킬술포닐기이고, R2는 수소 원자이고, R3및 R4가 수소 원자를 나타내고, R4가 메틸기인 화합물인 치료제.
  3. 제1항에 있어서, 일반식(Ⅰ)의 화합물중 R1이 메틸, n-프로필, 프로프-2-이닐, 시클로펜틸, 시클로펜틸메틸, 벤질 또는 N,N-디메틸카르복스아미도기 이고, R2및 R3가 R4가 수소 원자를 나타내고, R4가 메틸기인 화합물인 치료제.
  4. 제1항 내지 3항중 어느 하나의 항에 있어서, 일반식(Ⅰ)의 화합물 중 n이 2인 화합물인 치료제.
  5. 제1항에 있어서, 일반식(Ⅰ)의 화합물이 2, 3, 4, 5-테트라히드로-5-메틸-2-[(5-메틸-1H-이미다졸-4-일)메틸]-1H-피리도[4, 3-b]인돌-1-온 또는 생리학상 허용되는 그의 염 또는 용매화합물인 치료제.
  6. 제5항에 있어서, 화합물이 그의 염산염 형태로 사용되는 치료제.
  7. 제1항 내지 제6항중 어느 하나의 항에 있어서, 경구 투여에 적합한 의약제 또는 축적형 조제물로서의 의약제를 제조하기 위한 치료제.
  8. 제1 내지 제7항중 어느 하나의 항에 있어서, 단위 투여량 당 유효 성분 0.001 내지 100mg을 함유한 단위 투여 형태의 치료제.
  9. 제1 내지 제7항중 어느 하나의 항에 있어서, 단위 투여량 당 유효 성분 0.001 내지 10mg을 함유한 단위 투여 형태의 치료제.
  10. 제1 내지 제9항중 어느 하나의 항에 있어서, 약물 또는 남용물이 아편, 코카인, 벤조디아제핀, 알코올 또는 니코틴인 치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890012465A 1988-09-01 1989-08-31 의약제 KR900004339A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8820650.3 1988-09-01
GB888820650A GB8820650D0 (en) 1988-09-01 1988-09-01 Medicaments

Publications (1)

Publication Number Publication Date
KR900004339A true KR900004339A (ko) 1990-04-12

Family

ID=10643002

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890012465A KR900004339A (ko) 1988-09-01 1989-08-31 의약제

Country Status (9)

Country Link
EP (1) EP0357416A3 (ko)
JP (1) JPH02180823A (ko)
KR (1) KR900004339A (ko)
AU (1) AU627768B2 (ko)
CA (1) CA1330534C (ko)
DK (1) DK432789A (ko)
GB (1) GB8820650D0 (ko)
IL (1) IL91480A0 (ko)
ZA (1) ZA896676B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
JP2765845B2 (ja) * 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド 中止症候群の予防の治療薬
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
EP0272052B1 (en) * 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
DE3851597T2 (de) * 1987-09-03 1995-01-26 Glaxo Group Ltd., London Lactamderivate.

Also Published As

Publication number Publication date
DK432789A (da) 1990-03-02
EP0357416A3 (en) 1990-06-06
ZA896676B (en) 1990-06-27
AU4096689A (en) 1990-03-08
IL91480A0 (en) 1990-04-29
GB8820650D0 (en) 1988-10-05
JPH02180823A (ja) 1990-07-13
AU627768B2 (en) 1992-09-03
DK432789D0 (da) 1989-08-31
EP0357416A2 (en) 1990-03-07
CA1330534C (en) 1994-07-05

Similar Documents

Publication Publication Date Title
US20070116730A1 (en) Pharmaceutical compositions
RU2431486C2 (ru) Лекарственное средство для гигиеничного применения на ушах
JP2765845B2 (ja) 中止症候群の予防の治療薬
US20030130297A1 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
RU2005102105A (ru) Способы и лекарственные формы для контролируемой доставки палиперидона
ES2253423T3 (es) Formulacion de un ester de testosterona para uso humano.
PT92166B (pt) Metodo de preparacao de uma forma de dosagem com um reduzido potencial de abuso de droga
AU2002316582A1 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
KR19990067527A (ko) 동통의 치료를 위한 에피나스틴의 용도
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
KR20010032760A (ko) 수소화 피마자유를 함유하는 장기 활성을 나타내는 주사가능한 제형
KR880005930A (ko) 탐닉 치료용 의약품
KR880007074A (ko) 의약품
KR880007073A (ko) 의 약 품
CZ240297A3 (cs) Transdermální přípravek
NZ528935A (en) Method of delaying ejaculation
AU680539B2 (en) Use of ergoline derivatives for the treatment of glaucoma
Pontani et al. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
EP0514023B1 (en) Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
KR900004339A (ko) 의약제
EP0535237A1 (en) Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same
KR900004340A (ko) 의약제
US6680067B2 (en) Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid